

RNS Number : 7510W
Physiomics PLC
16 March 2026

16 March 2026

Physiomics plc
("Physiomics" or the "Company")

General Meeting Request

The directors of Physiomics plc (AIM: PYC) announce that at 2114h on 13 March 2026 they received a request submitted pursuant to section 303 of the Companies Act 2006 (the "**Act**") requiring the Board to convene a general meeting of the Company's shareholders (the "**GM Request**"). The GM Request was accompanied by a shareholder statement submitted pursuant to section 314 of the Act.

The GM Request has been submitted by Michael Whitlow, who the Board understands holds approximately 13.68% of the Company's issued ordinary share capital. The resolutions proposed in the GM Request comprise four separate resolutions which, if all passed, would have the immediate effect of appointing Nicholas Tulloch, Michael Whitlow, Ian Bagnall, and Martin Gouldstone as directors of the Company (the "**Appointment Resolutions**"). In addition, four further resolutions propose the removal of Dr Jim Millen, Shalabh Kumar, Dr Tim Corn, and Dr Peter Sargent as directors, each of which is conditional on at least two of the aforementioned Appointment Resolutions being passed. If all Appointment Resolutions are passed, and subsequently all of the removal resolutions are passed, this would result in the full replacement of the entire existing Board.

The Board is currently taking legal advice to confirm that the Request complies with the formal requirements of section 303 of the Act.

Subject to validation of the GM Request, and in accordance with section 304 of the Act, the Board will be required to give notice of a general meeting within 21 days of receipt of the Request (i.e., by no later than 3 April 2026). It is noted that the requisitioned general meeting notice, if valid, must be held on a date not more than 28 days after the date of the notice convening it, and in such circumstances the Company would circulate Mr Whitlow's section 314 statement together with the notice of the general meeting requested, as required by the Act.

It is noted that the directors had been approached by Mr Whitlow and were in dialogue with him at the time the GM Request was received. The directors are considering the GM Request carefully, however are united in their view that the wholesale replacement of the current Board would be highly detrimental to the Company and its shareholders. A further announcement will be made in due course.

For further information, please contact:

Physiomics plc
Dr Peter Sargent, CEO

+44 (0) 1235 841575

Hybridan LLP (Broker)
Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Limited (NOMAD)
James Dance & James Bellman

+44 (0) 20 7409 3494

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended).

Further information on the Company can be found on its website at www.physiomics.co.uk

The Company's LEI is 213800A71DSZ6ABMTQ91.

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCGZGMFMKRGVZZ